trial

Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia

NCTId NCT00423943
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 33 (actual)
Sponsored by University of California Riverside at C.I. Trials, Inc.-Inland Empire
Primary completion 2012-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
33 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2005-09
Primary completion
2012-12
Eligibility
ALL · 18 Years · 54 Years

Interventions & indications

Drugs
modafinil

Sponsors

University of California Riverside at C.I. Trials, Inc.-Inland EmpireLead Sponsor

Investigators

2
Michael J. Minzenberg, MDPrincipal Investigator
Cameron S Carter, MDPrincipal Investigator

Sites

1 total
Los Angeles, United States

Facts & assertions

4 sourced
Enrollment
33
Phase
PHASE4
Primary Completion Date
2012-12
Status
COMPLETED
relationships
The graph out of here
drug
modafinil
drug
lead_sponsor
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Michael J. Minzenberg, MD
person
Cameron S Carter, MD
person